摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2-二甲基-1H-苯并咪唑-5,6-二胺 | 90562-74-6

中文名称
1,2-二甲基-1H-苯并咪唑-5,6-二胺
中文别名
——
英文名称
1,2-dimethyl-5,6-diamino benzimidazole
英文别名
1,2-dimethyl-5,6-diaminobenzimidazole;1,2-dimethyl-1H-benzoimidazole-5,6-diamine;1,2-dimethyl-1H-benzimidazole-5,6-diyldiamine;1,2-Dimethyl-1H-benzimidazol-5,6-diyldiamin;1,2-dimethyl 5,6-diamino benzimidazole;1H-1,3-Benzimidazole-5,6-diamine, 1,2-dimethyl-;1,2-dimethylbenzimidazole-5,6-diamine
1,2-二甲基-1H-苯并咪唑-5,6-二胺化学式
CAS
90562-74-6
化学式
C9H12N4
mdl
MFCD00187846
分子量
176.221
InChiKey
WATNJQFGOVKPPQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    278 °C
  • 沸点:
    439.4±25.0 °C(Predicted)
  • 密度:
    1.37±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    69.9
  • 氢给体数:
    2
  • 氢受体数:
    3

SDS

SDS:2179e10f290f4e2cb5f695b896a39bb7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,2-二甲基-1H-苯并咪唑-5,6-二胺吡啶氯化亚砜 作用下, 以 为溶剂, 生成 5,6-dimethyl-5H-imidazo[4',5':4,5]benzo[1,2-c][1,2,5]thiadiazole
    参考文献:
    名称:
    Fridman,S.G.; Kotowa,L.I., Journal of general chemistry of the USSR, 1962, vol. 32, p. 2829 - 2838
    摘要:
    DOI:
  • 作为产物:
    描述:
    1,2-二甲基苯并咪唑 在 palladium on activated charcoal 硫酸氢气硝酸溶剂黄146 作用下, 以 乙醇 为溶剂, 反应 6.0h, 生成 1,2-二甲基-1H-苯并咪唑-5,6-二胺
    参考文献:
    名称:
    Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit
    摘要:
    Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is similar to 15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents. (C) 2003 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(03)00048-8
点击查看最新优质反应信息

文献信息

  • PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
    申请人:Yissum Research Development Company of the Hebrew University of Jerusalem
    公开号:US20020028817A1
    公开(公告)日:2002-03-07
    A preparation of a tyrphostin including a compound of a general formula: 1 wherein, for compound I, the preparation is enriched either for R 6 at position 6 or for R 6 at position 7, or, for Compound II, the preparation is enriched either for R 6 at position 6 or for R 6 at position 8.
    一种包括一般公式为:1的化合物的酪普司汀制备物,其中对于化合物I,制备物在位置6处或位置7处富集R6,或对于化合物II,制备物在位置6处或位置8处富集R6。
  • Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
    申请人:Sugen, Inc.
    公开号:US06329375B1
    公开(公告)日:2001-12-11
    The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    本发明涉及三环喹喔啉化合物及其生理上可接受的盐和前药,其调节蛋白酪氨酸激酶的活性,因此可用于预防和治疗蛋白酪氨酸激酶相关的细胞疾病,如癌症。
  • [EN] PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME<br/>[FR] COMPOSES PDGF INHIBITEURS DU RECEPTEUR DE KINASE, LEUR PREPARATION ET LEUR PURIFICATION, ET COMPOSITIONS PHARMACEUTIQUES A BASE DE CEUX-CI
    申请人:YISSUM RES DEV CO
    公开号:WO2001034607A1
    公开(公告)日:2001-05-17
    A preparation of a tyrphostin including a compound of a general formula (Compound I) or (Compound II), wherein, for (Compound I), the preparation is enriched either for R6 at position 6 or for R6 at position 7, or, for (Compound II), the preparation is enriched either for R6 at position 6 or for R6 at position 8.
    一种包括一般式化合物(化合物I)或(化合物II)的tyrphostin制剂,其中对于(化合物I),制剂在位置6处富集R6或在位置7处富集R6,或对于(化合物II),制剂在位置6处富集R6或在位置8处富集R6。
  • Fries, Justus Liebigs Annalen der Chemie, 1927, vol. 454, p. 204
    作者:Fries
    DOI:——
    日期:——
  • PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION AND COMPOSITIONS
    申请人:YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem
    公开号:EP1036067A2
    公开(公告)日:2000-09-20
查看更多